SABER Applauds Connecticut Lawmakers for Expanding Psychedelic Therapy Pilot Program

WASHINGTON, DC, March 11, 2026 (EZ Newswire) -- The Scientific Association for Botanical Education and Research (SABER) today commended the Connecticut and the Connecticut General Assembly for passing legislation to expand and strengthen the state’s psychedelic-assisted therapy pilot program — a move that aligns Connecticut with emerging federal regulatory pathways and positions the state as a responsible contributor to the growing body of clinical research on psychedelic-assisted therapies. 

The measure, recently advanced by lawmakers, updates the existing framework to better align with emerging federal regulatory pathways and anticipated review processes at the U.S. Food and Drug Administration. By refining eligibility criteria and extending the program’s operational timeline, Connecticut has positioned itself to contribute responsibly to the growing body of research surrounding psychedelic-assisted therapies.

SABER supports policies that encourage rigorous scientific evaluation while maintaining appropriate clinical safeguards. The expansion reflects a research-driven approach that recognizes the increasing volume of peer-reviewed literature on psychedelic-assisted interventions for serious mental health conditions while ensuring that patient safety and institutional oversight remain central.

“State-level pilot programs that are embedded within academic medical centers create an opportunity to generate high-quality clinical data under controlled conditions,” said Dr. Mary Hardy, a member of SABER’s Scientific Steering Committee. “When investigational therapies are studied within structured protocols that include defined dosing parameters, screening criteria, adverse event monitoring, and independent oversight, the resulting data can meaningfully inform both federal review processes and long-term public health policy. Ultimately, this is about ensuring that patients have access to safe, well-studied therapies grounded in real clinical evidence. High-quality scientific research in this field is essential for safe, effective clinical care and appropriate regulation to ensure access without sacrificing quality.”

About Scientific Association for Botanical Education and Research (SABER)

Media Contact

Paloma Lehfeldt
[email protected]

You May Also Be Interested In

• Businesses Lose Brand Impact Without Custom Signage Printing
• Beijing Review: Progress Through Participation
• SuperX AI Technology Discusses Proposed 1GW AI Computing Park with Kazakhstan Prime Minister to Explore Central Asia's Digital Infrastructure Market